The management of hyponatremia in cancer patients: a practical view in Spain

Abstract

Hyponatremia is a common disorder among cancer patients and is associated with a poor prognosis in several malignancies. It is classified by volemic status into hypovolemic, euvolemic, and hypervolemic hyponatremia. Clinical history, physical examination, and blood and urine tests are important for a correct classification and diagnosis of hyponatremia, to assure correct management. Treatment of hyponatremia in cancer patients depends on the etiology of hyponatremia, as well as on the chosen therapy for the tumor. Supportive care is also a factor to be taken into account.

Keywords

Hyponatremia / sodium / cancer / syndrome of inappropriate antidiuretic hormone secretion / antidiuretic hormone / supportive care

References

[1] De las Peñas R,Henao F,Rodríguez CA.SEOM guidelines on hydroelectrolytic disorders..Clin Transl Oncol2014;16:1051-9 PMCID:PMC4239780

[2] Verbalis JG,Greenberg A,Schrier RW.Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations..Am J Med2013;126:S1-42

[3] Marquina G,Manzano A,Aguado C.Incidence, classification and diagnosis of hypo- natremia in patients admitted to the oncology ward..J Clin Oncol2015;33:e20656

[4] Castillo JJ,Boklage SH,Tidwell BA.The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients..BMC Cancer2016;16:564 PMCID:PMC4966824

[5] Berardi R,Caramanti M,Santoni M.Hyponatremia in cancer patients: time for a new approach..Crit Rev Oncol Hematol2016;102:15-25

[6] Zylberman M.Incidencia y mortalidad de la hiponatremia en pacientes con cáncer..Diálisis Traspl2010;10:

[7] Djamgoz MBA,Brackenbury WJ.In vivo evidence for voltage-gated sodium channel expression in carcinomas and potentiation of metastasis..Cancers2019;11:1675 PMCID:PMC6895836

[8] Berardi R,Rinaldi S,Smerilli A.Risk of hyponatraemia in cancer patients treated with targeted therapies: a systematic review and meta-analysis of clinical trials..PLoS One2016;11:e0152079 PMCID:PMC4864354

[9] Bengus A.Hyponatremia - predictor of adverse prognosis in cirrhosis..J Med Life2012;5:176-8 PMCID:PMC3391887

[10] Doshi SM,Lei X,Salahudeen AK.Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes..Am J Kidney Dis2012;59:222-8

[11] Abu Zeinah GF,Hassan AA.Hyponatraemia in cancer: association with type of cancer and mortality: hyponatraemia and cancer mortality..Eur J Cancer Care (Engl)2015;24:224-31

[12] Castillo JJ,Justice E.Diagnosis and management of hyponatremia in cancer patients..Oncologist2012;17:756-65 PMCID:PMC3380874

[13] Hiponatremia en oncología. Nefrología [Internet]. 2011. Available from: http://doi.org/10.3265/NefrologiaSuplementoExtraordinario.pre2011.Sep.11149

[14] Peri A.Prognostic and predictive role of hyponatremia in cancer patients..J Cancer Metastasis Treat2019;5:40

[15] Ball SG.Diagnosis and treatment of hyponatraemia..Best Pract Res Clin Endocrinol Metab2016;30:161-73

[16] Aylwin S,Peri A,Thatcher N.‘Dos and don’ts’ in the management of hyponatremia..Curr Med Res Opin2015;31:1755-61

[17] Tzoulis P.Peri A,Verbalis JG.The diagnostic approach to the patient with hyponatremia: are the correct investigations being done?.Frontiers of Hormone Research.2019;S. Karger AG190-9

[18] Ploutarchos T.Hyponatraemia in clinical practice: are we investigating and treating appropriately? In Disorders of fluid and electrolyte metabolism. FOCUS: Hyponatremia..Hormone Research 2019. Frontiers of Hormone Research2019;52:190-199

[19] Runkle I.Gomez-Hoyos E.El diagnóstico diferencial de la hiponatremia..Manual Enigmas de la Hiponatremia.2018;BarcelonaPermanyer11-13

[20] Petereit C,Teber I,Grohé C.A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan..BMC Pulm Med2013;13:55 PMCID:PMC3851291

[21] Onitilo AA,Doi SAR.Tumor-related hyponatremia..Clin Med Res2007;5:228-37 PMCID:PMC2275758

[22] Runkle I,Cuesta-Hernández M,de Miguel P.Hyponatraemia in older patients: a clinical and practical approach..Rev Clin Gerontol2015;25:31-52

[23] Furst H,Post J,Kotzker W.The urine/plasma electrolyte ratio: a predictive guide to water restriction..Am J Med Sci2000;319:240-4

[24] Johansson P,Strömberg A,Jaarsma T.Fluid restriction in patients with heart failure: how should we think?.Eur J Cardiovasc Nurs2016;15:301-4

[25] Pose A,Manzano L,López Granados A.Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan..Rev Clin Esp2017;217:398-404

[26] Schrier RW,Orlandi C.Tolvaptan, a selective oral vasopressin v2-receptor antagonist, for hyponatremia..N Engl J Med2006;355:2099-112

[27] Verbalis JG,Schrier RW,Zhao Q.Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion..Eur J Endocrinol2011;164:725-32 PMCID:PMC3573862

[28] Berardi R,Blasi L,Lorusso V.Practical issues for the management of hyponatremia in oncology..Endocrine2018;61:158-64

[29] Escobar AY, Henao CF, de las Penas Bataller R, Rodríguez CA. Algoritmo de tratamiento de la hiponatremia asociada al SIADH en el paciente oncológico. Sociedad Española de Oncología Meédica 2014. Available from: http://www.seom.org/es/publicaciones/publicacionesseom/104548-algoritmo-seomdel-manejo-de-la-hi-ponatremiaen-el-paciente-oncologico [Last accessed on 21 Feb 2020]

[30] Runkle I,Navarro A,Formiga F.El tratamiento de la hiponatremia secundaria al síndrome de secreción inadecuada de la hormona antidiurética..Med Clin (Barc)2013;141:507e1-10